CTOs on the Move

Tower Health

www.towerhealth.org

 
Tower Health is a regional integrated healthcare system that offers leading-edge, compassionate healthcare and wellness services to communities in Berks, Chester, Montgomery, and Philadelphia Counties. With nearly 12,000 team members, Tower Health consists of Reading Hospital in West Reading; Chestnut Hill Hospital in Philadelphia; Phoenixville Hospital in Phoenixville; Pottstown Hospital in Pottstown; and St. Christopher`s Hospital for Children, a partnership of Tower Health and Drexel University in Philadelphia. It also includes Reading Hospital Rehabilitation at Wyomissing; Reading Hospital School of Health Sciences in West Reading; home healthcare provided by Tower Health at Home; TowerDirect ambulance and emergency response; Tower Health ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Eugene Reilly
 Vice President and Chief Medical Information Officer Profile
Teresa Grogan
 VP and Chief Information Security Officer Profile
Thomas Bartiromo
 Vice President and Chief Technology Officer Profile
Thomas Bartiromo
 Vice President and Chief Information Officer Profile
Jonathan Banks
 Interim VP and Chief Information Security Officer Profile

Similar Companies

HIT Global

SonarMed

SonarMed is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Heartbeat Health

A new standard for virtual heart care. Heartbeat is a complete telehealth platform for cardiology that incorporates telemedicine, remote diagnostics, and digital heart health programs. Learn more

PharmaDesign

PharmaDesign is a Warren, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.